9-ing-41
Small moleculeexperimental
Clinical trial activity
10 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03678883)
Timeline
Indications
Studied for
- Bone Neoplasms · Phase 1/Phase 2
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Adenoid Cystic · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Fibrosarcoma · Phase 2
- Glioma · Phase 1/Phase 2
- Hemangiosarcoma · Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Leiomyosarcoma · Phase 2
- Liposarcoma · Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Meningioma · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 1
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 2
- Primary Myelofibrosis · Phase 2
- Rhabdomyosarcoma · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Sarcoma, Synovial · Phase 2
Mechanism of action
- Glycogen synthase kinase-3 betaINHIBITOR
GSK3B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1C=C(C2=C1C=C3OCOC3=C2)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(F)C=C6- Mol. weight
- 404.3474 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSND1SOF0DLU ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06896188 | Phase 1 | Sep 22, 2025 | Actuate Therapeutics Inc., Incyte, University of Pittsburgh |
| NCT05077800 | Phase 2 | Mar 31, 2022 | Actuate Therapeutics Inc., Harvard University, Lustgarten Foundation |
| NCT05116800 | Phase 2 | Mar 1, 2022 | Actuate Therapeutics Inc., Brown University, Lifespan Cancer Institute |
| NCT05239182 | Phase 2 | Jan 26, 2022 | Actuate Therapeutics Inc., Incyte, University of Kansas |
| NCT04906876 | Phase 2 | Sep 30, 2021 | Actuate Therapeutics Inc., Brown University, Lifespan Cancer Institute |
| NCT04832438 | Phase 2 | Sep 18, 2021 | Actuate Therapeutics Inc., Harvard University |
| NCT05010629 | Phase 2 | Sep 14, 2021 | Actuate Therapeutics Inc., Harvard University |
| NCT04239092 | Phase 1 | Apr 30, 2020 | Actuate Therapeutics Inc., Developmental Therapeutics Consortium |
| NCT04218071 | Phase 2 | Mar 31, 2020 | Actuate Therapeutics Inc., Developmental Therapeutics Consortium |
| NCT03678883 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2018 | Actuate Therapeutics Inc., Developmental Therapeutics Consortium |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc. | For profit | 10 | 4 | 2 | 2018 |
| Developmental Therapeutics Consortium | Academic/Hospital | 3 | 0 | 2 | 2018 |
| Harvard University | Academic/Hospital | 3 | 2 | 1 | 2021 |
| Brown University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Incyte | For profit | 2 | 0 | 2 | 2022 |
| Lifespan Cancer Institute | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2025 |
9 organizations
Page 1 / 1